This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 1999 Oct 20;282(15):1474-5.

doi: 10.1001/jama.282.15.1474.

Conflict of interest and cost-effectiveness analysis

PMID: 10535440
DOI: 10.1001/jama.282.15.1474

Editorial

Conflict of interest and cost-effectiveness analysis

S Krimsky. JAMA. 1999.

. 1999 Oct 20;282(15):1474-5.

doi: 10.1001/jama.282.15.1474.

Author

PMID: 10535440
DOI: 10.1001/jama.282.15.1474

No abstract available

PubMed Disclaimer

Comment in

Sources of bias in the economic analysis of new drugs. Health Outcomes Committee Pharmaceutical Research and Manufacturers of America, Washington, DC.
Gagnon JP. Gagnon JP. JAMA. 2000 Mar 15;283(11):1423; author reply 1424. JAMA. 2000. PMID: 10732925 No abstract available.

Comment on

Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Friedberg M, et al. JAMA. 1999 Oct 20;282(15):1453-7. doi: 10.1001/jama.282.15.1453. JAMA. 1999. PMID: 10535436

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems